The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance
Recruiting · NCT06224634 · Observational (researchers observe without assigning treatment) · Lead sponsor: Copenhagen University Hospital, Hvidovre
View the official record on ClinicalTrials.gov →What this trial is about
This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance. The study involves adult participants suffering from dermatological or rheumatological illness, who are planning to start treatment with monoclonal antibodies targeting interleukin 17 as a part of the treatment of these diseases. The primary outcome of this study will be changes in airway hyperresponsiveness to methacholine challenge reported as response-dose-ratio before and after initiation of anti-IL17 treatment regardless of presence of respiratory disease. Furthermore, the potential effect of anti-IL-17 on airway resistance will be assessed using conventional spirometry for measuring changes in FEV1 and Airwave oscillometry. A reduced degree of airway hyperreactivity and airway resistance after initiating ani-IL-17 could indicate effectiveness of anti-IL-17 in asthma patients which would have to be examined further in a population of asthma patients.
Who can take part
Inclusion criteria
- Patients planning to start treatment with anti-IL-17 antibodies
Exclusion criteria
- Current pregnancy
- FEV1 \< 1.5L or less than 60% of predicted value expected.
- Previous anaphylactic shock or severe allergic reaction to medicine
- Uncontrolled hypertension
- Myocardial infarction or stroke within the last 3 months
- Known aortic aneurysm
- Recent eye surgery or risk of elevated intracranial pressure
- Treatment with systemic corticosteroids within 6 weeks
Where it is running
1 location listed.
- Respiratory Research Unit Hvidovre Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Capital Region, Denmark